DIAPH3 promotes pancreatic cancer progression by activating selenoprotein TrxR1-mediated antioxidant effects

Yefei Rong1 | Jie Gao2,3 | Tiantao Kuang1 | Jianlin Chen2,3 | Jian-ang Li1 | Yufeng Huang4 | Haiguang Xin5 | Yuan Fang1 | Xu Han1 | Lun-Quan Sun2,3 | Yue-Zhen Deng2,3 | Zhi Li2,3 | Wenhui Lou1

Abstract
Pancreatic cancer is a highly malignant tumour of the digestive tract which is difficult to diagnose and treat. Approximately 90% of cases arise from ductal adenocarcinoma of the glandular epithelium. The morbidity and mortality of the disease have increased significantly in recent years. Its 5-year survival rate is <1% and has one of the worst prognoses amongst malignant tumours. Pancreatic cancer has a low rate of early-stage diagnosis, high surgical mortality and low cure rate. Selenium compounds produced by selenoamino acid metabolism may promote a large amount of oxidative stress and subsequent unfolded reactions and endoplasmic reticulum stress by consuming the NADPH in cells, and eventually lead to apoptosis, necrosis or necrotic cell death. In this study, we first identified DIAPH3 as a highly expressed protein in the tissues of patients with pancreatic cancer, and confirmed that DIAPH3 promoted the proliferation, anchorage-independent growth and invasion of pancreatic cancer cells using overexpression and interference experiments. Secondly, bioinformatics data mining showed that the potential proteins interacted with DIAPH3 were involved in selenoamino acid metabolism regulation. Selenium may be incorporated into selenoprotein synthesis such as TrxR1 and GPX4, which direct reduction of hydroperoxides or resist ferroptosis, respectively. Our following validation confirmed that DIAPH3 could down-regulate cellular ROS level via up-regulating TrxR1 expression. Finally, nude mice xenograft model experimental results demonstrate DIAPH3 knock down could decrease tumour growth and TrxR1 expression and ROS levels in vivo. Collectively, our observations indicate DIAPH3 could promote pancreatic cancer progression by activating selenoprotein TrxR1-mediated antioxidant effects.
1 | INTRODUCTION

Pancreatic ductal adenocarcinoma (PDAC) is the third most fatal tumour in the United States. It is estimated that the deaths from pancreatic cancer will be second only to lung cancer by 2030. However, due to lack of effective treatment, the 5-year survival rate of PDAC patients is still lower than 7%. Gemcitabine is a nucleoside analog that received FDA approval in 1997, and it is still a medicine used in the standard treatment of pancreatic cancer. Adjunctive therapies with Paclitaxel and Erlotinib show a limited curative effect in the treatment of pancreatic cancer. Other treatment options for pancreatic cancer (such as FOLFIRINOX) are highly toxic and only applicable to some patients. At present, the main genetic driving factors of PDAC have been identified, of which KRAS is the main driver mutation, and the mutations of several other tumour suppressor genes such as TP53, CDKN2A, SMAD4, BRCA2 and TGFBR2 can promote tumour progression. Unfortunately, as yet there are no targeted medications for these cancer-driven genes; therefore, it is difficult to design an effective treatment method for PDAC. Only a small proportion of clinically relevant mutations may benefit from existing targeted therapies.

Both mouse and human Formin family proteins contain 15 Formin proteins, characterized by the presence of two formin homology domains. By interacting with the growing ends of actin filaments, Formins can protect it from capping, catalyse the polymerization of actin and regulate the formation of filamentous pseudopods to support the establishment and maintenance of cell polarity during the development process and in response to disease. Diaphanous formins (including Diaph1, 2 and 3 in mammals) are a subgroup of the Formin family that is homologous to the fruit fly diaphanous gene. Diaph1-3 exists in two forms. In an inactivated ‘locked’ form, the carboxy-terminal diaphanous self-regulating domain interacts with the upstream inhibitory domain. The binding of the small GTPase to the GTPase-binding domain disrupts the interaction between the inhibitory domain and the diaphanous self-regulatory domain, and releases the protein ends, thereby promoting the activation of the Diaph protein.

In Drosophila, mutations in the diaphanous gene cause defects in gamete genesis and neuroblast formation, which are accompanied by defects in cell division caused by polyploids. In mammals, Diaph1-3 mutations are associated with local actin cytoskeletal dysfunctions. For example, in Diaph1 and 2 double-knockout (Diaph1-2 dko) mice, the radial migration and layer formation of cortical excitatory neurons are basically unaffected, while the tangential migration of cortical interneurons and neuroblasts is impaired from the adult neurogenic subventricular zone (VZ) to the olfactory bulb. F-actin tissues are destroyed in the migrated interneurons and posterior neuroblasts, thereby weakening the centrosome and nucleus translocation. Diaph3 is accumulated in the cleavage furrow from the anaphase to the telophase of cell division, and its depletion in the dividing cells in vitro will affect the F-actin content of the equatorial plate region. In Diaph3-deficient mice, erythroid cells differentiate normally, but in the telophase of erythroblast cell division, as the actin has not accumulated as much in the cleavage furrow, the progeny cells cannot be separated. Diaph3 overexpressed mice showed internal abnormalities in hair cells. These mice exhibited hearing loss, suggesting that Diaph3 plays an important role in the assembly and/or maintenance of actin filaments in stereocilia. In humans, mutations in the 5′-untranslated region of the messenger RNA encoding DIAPH3 cause an increase in the expression level of DIAPH3 protein by two to three times compared to normal levels, leading to delayed progressive deafness, which is known as a non-syndrome dominant chromosome inheritance of auditory neuropathy. In addition, homozygous mutations in the DIAPH3 gene (maternal genetic deletion of 13q and point mutations in the paternal copy) are associated with autism. In addition to its well-documented role in the actin cytoskeleton, in vitro studies have demonstrated that Diaph3 is associated with the dynamics of microtubules (MTs). Diaph3 is co-localized with stable MT, and its overexpression is sufficient to generate and target stable MT14. Diaph3 can directly bind (and stabilize) MTs in a way that is independent of actin nucleation. In some literatures, it was reported that Diaph3 interacts with MT tip protein EB1 and colorectal adenomatous polyposis genes (APC) to function as a scaffolding of proteins.

The function of DIAPH3 in tumours differs depending on the tumour type. In prostate and breast cancer cells, DIAPH3 induces nuclear morphological instability and promotes malignant tumour phenotypes. Consistently, DIAPH3 promotes the growth, migration and metastasis of liver cancer cells by activating the β-catenin/TCF signalling pathway. Furthermore, in mouse models, interference with DIAPH3 promotes the invasion and metastasis of tumour cells. The DIAPH3 overexpression inhibits the metastasis and invasive ability of triple-negative breast cancer by inhibiting the expression of RhoA-GTP. However, the specific mechanism of DIAPH3 in the occurrence and development of pancreatic cancer is still unknown.

Excess cytosolic ROS is eliminated by peroxiredoxins using reducing power from thioredoxin reductase-1 (TrxR1. TXNRD1) or by glutathione peroxidases using reducing power from glutathione reductase (Gsr). TrxR1 is a key enzyme for redox control of cell function and antioxidant capacity. Many cancer cells have high levels of TrxR1 as a means of surviving their increased endogenous.

**KEYWORDS**
DIAPH3, pancreatic cancer, Selenoamino Acid Metabolism, TrxR1
oxidative stress. Thus, TrxR1 is a promising target for improved cancer therapy.\textsuperscript{28}

In this study, we investigated the expression pattern, function and molecular mechanism of DIAPH3 in pancreatic cancer, and our observations indicate DIAPH3 could promote pancreatic cancer progression by activating selenoprotein TrxR1-mediated antioxidant effects.

2 | MATERIALS AND METHODS

2.1 | Cell culture

All PDAC cell lines were provided by Professor Yue-zhen Deng from Xiangya Hospital, Central South University. PDAC cell lines were cultured in DMEM (Gibco) medium containing 10% FBS (Gibco). All cell lines were cultured in a 37°C, 5% CO\textsubscript{2} cell incubator.

2.2 | mRNA extraction and Real-time PCR

mRNA was extracted using a TRIzol reagent (Invitrogen, 15 596-026). A reverse transcription kit was used to reversely transcribe cDNAs for Real-time PCR. The amplification reaction was carried out using a Bio-Rad system. The reaction system was 20 μl, including 10 μl of SYBR Green Mix, 10 μM forward and reverse primers, 1 μl each, 2 μl of template and 6 μl of riboyme-free water. The reaction programme was as follows: 95°C for 3 minutes followed by 40 cycles of the reaction, each cycle comprised 95°C for 10s, 60°C for 30s. In order to determine the amplification specificity, the amplification products of each primer pair were subjected to melting curve analysis.

The primer sequences used were as follows:

- **DIAPH3**
  - Forward: 5’- GAAACACGGTTGGCAGAGTCT-3’
  - Reverse: 5’- GTGGCCGTAGTCTCTTCACA-3’

- **β-actin**
  - Forward: 5’- GATCATTGCTCCTCCTGAGC-3’
  - Reverse: 5’- ACTCCTGCTTGCTGATCCAC-3’

2.3 | Whole protein extraction with western blot

After washing with pre-cooled PBS, cells were lysed with a RIPA lysis buffer (1% NP-40, 0.1% SDS, 0.5% deoxycholate, 50mM Tris (pH 7.4), Protease Inhibitor Cocktail) for 15 min on ice. After the cells were completely lysed for 15 minutes, the mixture was then centrifuged for 15 min at 4°C, and the supernatant was then transferred. The protein concentration in the lysate was quantitatively analysed with a BCA (Sigma) reagent. The quantified protein was adjusted to the same concentration according to the result of quantitative analysis, then a 4 x loading buffer was added and mixed, and the protein was denatured at 100°C for 5 min. After it was slightly cooled and centrifuged, the protein was subjected to SDS-PAGE gel electrophoresis. After electrophoresis, the proteins on the SDS-PAGE gel were transferred to PVDF membranes (polyvinylidene difluoride membranes, Millipore), and then the target protein bands were cut and blocked at room temperature for 1 hour with TBST containing 5% skim milk powder (25 mM Tris, 150 mM NaCl, 0.05% Tween-20, pH 7.5), then incubated overnight at 4°C with primary antibodies. The primary antibodies used were DIAPH3 (Abcam), Tubulin (Santa Cruz). The following day, after washing three times with TBST, a secondary antibody was added for incubation for 1 hour at room temperature, and washed three times with TBST, then developed with a millipore luminescent solution.

2.4 | ICP-MS analysis

Cells were washed and acid digested. Plates were rapidly washed three times with 100 ml per well of TE buffer (10 mM Tris pH 7.4, 1 mM EDTA). Digestion mix (100 ml per well) was added to all wells and contained 1.5% nitric acid (w/v), 1.5% hydrogen peroxide (w/v) and 50 pp.b. Ga as an internal standard. Finally, plates were placed in a humidified incubator at 70°C for 2 h. All digested plates were sealed to prevent evaporation and stored at −80°C until ICP-MS analysis. ICP-MS analyses were performed at Shanghai USEN Biological Technology Co., Ltd equipped with Agilent Technologies ICP-MS 7500cs (Santa Clara, CA) and a ESI SC-4 high-throughput autosampler.

2.5 | RNA interference

pLKO.1 lentiviral vector was used to construct shRNA targeting the human DIAPH3 gene in PDAC cells. In order to effectively knock down the expression of DIAPH3 in PDAC cells, we designed and synthesized complementary oligonucleotides, which were annealed and complemented to the linearized pLKO.1 vector. We shared the following two pairs of oligonucleotides for the synthesis of DIAPH3-shRNA.

- **sh DIAPH3-1**
  - F: 5’-CCGGCCTGTCAGAATAGCTAAAGAACTCGAGTTCTTTAGCTATTCTGACACGTTTTTTG-3’
  - R: 5’-AATTCAAAAAACGTGTCAGAATAGCTAAAGAACTCGAGTTAAAGAGAATAGCACTGAGC-3’

- **sh DIAPH3-2**
  - F: 5’-CCGGGCTCAGTGCTATTCTCTTTAACTCGAGTTAAAGAGAATAGCACTGAGC-3’
  - R: 5’-AATTCAAAAAAGCTCAGTGCTATTCTCTTTAACTCGAGTTAAAGAGAATAGCACTGAGC-3’
2.6 | CCK-8 proliferation assay

Cells in a logarithmic growth phase were inoculated into a 96-well plate, $10^3$ cells in each well, and three replicates were established for each group. On the first, third and fifth days, CCK-8 was added on a 1:10 (by volume) ratio of CCK-8:culture medium, and incubated at 37°C for 1 h. The absorbance was measured at a wavelength of 460.

2.7 | Transwell invasion assay

70 µL of Matrigel diluted with a basal medium (100:3) was added to the centre of the bottom membrane of the upper chamber and incubated at 37°C for 30 minutes to solidify. A cell suspension was prepared with a culture solution containing 0.1% FBS, and its density was adjusted to $5 \times 10^5$ cells/ml. Then, 200 µL of the cell suspension was inoculated into the upper chamber, and 500 µL of a medium containing 10% FBS was added to the 24-well lower chamber, then placed in an incubator at 37°C and 5% CO2 for 48 hours, then subsequently fixed with 4% paraformaldehyde and stained with crystal violet. Five fields of view were randomly selected for observation by a 20-fold microscope, then photographed and counted with Image J software to calculate the relative invasion rate.

2.8 | Colony formation in soft agar

Double-layer agar was used in a 24-well plate, and the lower layer of agar was used to isolate the plate bottom. $1 \times 10^3$ cells were mixed with the upper layer of agar and then inoculated into the 24-well plate. Two weeks later, the non-anchored growth condition of cells was observed and photographed, and then statistical analysis was performed.

2.9 | Silver staining

A Beyotime silver staining kit was used for silver-staining analysis.

2.10 | Bioinformatics analysis

The DIAPH3 interacting protein network diagram was drawn with cytoscape software. The GO analysis of the DIAPH interacting protein was detected with mass spectrometry and the network construction of the interacting proteins was completed using the Metascape website (http://metascape.org/gp/index.html#main/step1) and visualized with Cytoscape.

2.11 | Measurement of ROS

Intracellular accumulation of ROS was determined using the fluorescent probes 2', 7'-dichlorodihydrofluorescein diacetate (H2DCFDA). Miapaca-2 and CFPAC-1 cells were pretreated with 20 µM H2O2 for 30 minutes. Cells were then stained with the fluorescent dye DCFDA for an additional 10 minutes. Then, cells were washed in PBS twice, and fluorescence was detected by fluorescence microscope. Meanwhile, the ROS levels were measured by flow cytometry and analysed using the FlowJo software.

2.12 | Mouse models

All the experimentation for animals was approved by Animal Ethics Committee of Fu Dan University, following the Guidelines of Animal Handling and Care in Medical Research from Shanghai, China. For human PDAC xenograft model, 6–8 weeks old male nude mice were from Hunan SJA Laboratory animal company. Mia Paca-2 cells ($1.7 \times 10^6$) or CFPAC-1 cells ($3.0 \times 10^6$) virally transformed with control vector or sh-DIAPH3 were injected into the left (shDIAPH3) and right (control vector) flank of nude mice for PDAC tumour formation, respectively.

2.13 | IHC staining assay

The samples of PDAC tissue arrays or syngeneic tumour were subjected to heat-mediated antigen retrieval in 0.01 mol/l citrate buffer (pH 6.0). After cooling to room temperature, samples were treated successively with 1% methanol/30% H2O2 to block endogenous peroxidase and 5% bovine serum albumin to block nonspecific binding sites. After rinsing with PBS, they were incubated overnight at 4°C with the Rabbit-anti-DIAPH3 or Rabbit-anti-TrxR1 primary antibody. The sections were then rinsed with PBS and incubated with the HRP conjugated secondary antibody for 30 min at room temperature. Then the sections were washed and incubated with DAB (Abcam, Cambridge, UK) and were terminated by rinsing with distilled H2O. Finally, the samples were counterstained with haematoxylin.

3 | RESULTS

3.1 | DIAPH3 Expression was up-regulated in Pancreatic Cancer

Pancreatic cancer has a high malignancy and poor survival prognosis. Therefore, the study on the effect of cancer-promoting genes on the occurrence and development of pancreatic cancer and further understanding of its mechanism can provide better basis for the treatment of pancreatic cancer. According to the database GEPIA (Gene Expression Profiling Interactive Analysis), we found that the DIAPH3 expression was significantly up-regulated in pancreatic cancer, and the expression level of DIAPH3 in tumour tissues of patients with pancreatic cancer was 6–7 times that of normal tissue (Figure 1A). We further analysed the data in the TCGA database UALCAN and confirmed the up-regulated expression of DIAPH3 in pancreatic cancer, and this
up-regulation multiple gradually increased along with the progression of pancreatic cancer (Figure 1B). In support of this data-mining result, we verified DIAPH3 was overexpressed in pancreatic tumour tissues over adjacent tissues with paired clinical samples (Figure 1C-D). Further analysis showed that patients with high expressions of DIAPH3 in pancreatic cancer had a shorter survival than patients with low expressions (Figure 1E and Figure 1F). qPCR result showed that the transcription level of DIAPH3 in several pancreatic cancer cells was higher than that of normal pancreatic cells HPDE (Figure 1G), and a similar conclusion was obtained at the protein level (Figure 1H). Overall, the expression of DIAPH3 is up-regulated in pancreatic cancer and may be closely associated with the occurrence and development of pancreatic cancer.
Proliferation of pancreatic cancer cells was promoted by DIAPH3

In order to further study the function of DIAPH3 in pancreatic cancer cells, we established a stable overexpressing cell line of DIAPH3 in pancreatic cancer cells SW1990 and MiaPaca-2 (hereinafter referred to as Mia Paca-2) (Figure 2A and Figure S1A). The cell proliferation rate was measured with a CCK8 assay, and it was found that the proliferation rate of pancreatic cancer cells overexpressing DIAPH3 was significantly higher than that of the control cells. The same results were observed in both SW1990 and Mia Paca-2 pancreatic cancer cells (Figure 2B and Figure S1B). In order to further verify the functions of DIAPH3 in promoting the proliferation of pancreatic cancer, we designed an shRNA targeted to human DIAPH3, constructed DIAPH3 stable knock down cell line in Mia Paca-2 and CFPAC-1 cells and tested its knock down efficiency using Western Blot (Figure 2C). Compared
with control cells, both shRNAs can effectively knock down DIAPH3 in different cell lines. After knocking down DIAPH3 in pancreatic cancer cells, its proliferation rate was significantly inhibited (Figure 2D). We then constructed another two DIAPH3 knock down cell lines in SW1990 and HPDE. In accordance with these two knock down cell lines results, knock down of DIAPH3 significantly decreased proliferation capacity of SW1990 and HPDE cells (Figure S1C-F). Collectively, we regulated the expression level of DIAPH3 in pancreatic cancer cells and found that DIAPH3 could indeed promote the proliferation of pancreatic cancer cells.

3.3 | DIAPH3 promotes pancreatic cancer cell invasion

Pancreatic cancer has an extremely low survival rate because of its high degree of malignancy and the subsequent multiple metastases during the early stages. Therefore, we should study the metastasis of pancreatic cancer in addition to its occurrence and development. Given that we have discovered the regulatory function of DIAPH3 on the proliferation of pancreatic cancer cells (Figure 2), we further investigated the effect of DIAPH3 on the invasive capacity of pancreatic cancer cells. We used the cell lines established in pancreatic cancer cells to conduct our study and found that DIAPH3 could regulate the invasive capacity of pancreatic cancer cells. The cell invasive capacity was detected using a Transwell assay. After overexpressing DIAPH3 in pancreatic cancer cells, its invasive capacity was greatly enhanced, which was verified in SW1990 cell lines (Figure 3A and C), while DIAPH3 did not affect cell proliferation under this low serum culture concentration (0.1%) within 48 hours (Figure S2A), which rules out the possibility of false-positive observation of DIAPH3 enhanced invasion resulted from DIAPH3-induced proliferation. In order to further confirm this function, we also used pancreatic cancer cell lines Mia Paca-2 and CFPAC-1 with DIAPH3 knock down to conduct a study and found that the invasive capacity of pancreatic cancer cells was greatly weakened after knock down of DIAPH3 (Figure 3B and D), likewise, DIAPH3 did not have an impact on cell proliferation of Mia Paca-2 and CFPAC-1 under this low serum culture concentration (0.1%) within 48 hours (Figure S2B and C). In summary, DIAPH3 can promote the invasive capacity of pancreatic cancer cells.

3.4 | DIAPH3 promotes tumour formation/non-anchored growth of pancreatic cancer cells

After confirming the effect of DIAPH3 on the occurrence and metastasis of pancreatic cancer, we further confirmed its effect on the development of pancreatic cancer. When overexpressing DIAPH3, the non-anchored growth ability of pancreatic cancer cells SW1990 was significantly up-regulated (Figure 4A and C). Similarly, when we knocked down DIAPH3 in pancreatic cancer cells Mia Paca-2 and CFPAC-1, the non-anchored growing ability of pancreatic cancer cells was significantly blocked (Figure 4B and D). Therefore, it is possible to inhibit the progression of pancreatic cancer through DIAPH3 interference.

3.5 | bioinformatic analysis shows DIAPH3 may promote pancreatic cancer progression via regulation of selenoamino acid metabolism

In order to study the molecular mechanism of DIAPH3 in promoting the progression of pancreatic cancer, we screened DIAPH3

**Figure 4** DIAPH3 promotes tumour formation and non-anchored growth ability of pancreatic cancer cells. (A and C) (A) Non-anchored growth ability of DIAPH3 overexpressed cell lines SW1990 was investigated by soft agar assay and statistical analysis was presented in (C), Error bars denote mean ± SEM. (B and D) Non-anchored growth ability of DIAPH3 knock down PDAC cell lines Mia Paca-2 and CFPAC-1 established in Figure 2C was investigated using soft agar assay, and statistical analysis was presented in (D), Error bars denote mean ± SEM. ***P < 0.0001, Mann-Whitney test. All experiments were repeated three times.
interaction proteins by mass spectrometry (Figure 5A). A total of 116 DIAPH3-specific interacting proteins were identified by mass spectrometry (Table S1), among which RPS8, IARS, RPL4, RPL6 and RPS2 are top 5 most identified proteins. Through GO analysis on the Metascape website, we found that the interacting proteins of DIAPH3 were mainly selenoamino acid metabolic enzymes (Figure 5B, C, E, F), indicating that DIAPH3 may affect the metabolism of selenoamino acids in pancreatic cancer. We further investigated the GO analysis results and performed similarity correlation of significantly enriched GO terms in the interacting proteins, and found that genes of the selenoamino acid metabolic pathways were independent of the GO terms of other enrichment analysis compared with other
DIAPH3 interacting proteins with a smaller P value; therefore, it showed an extremely significant enrichment (Figure 5D, E, G, H). Further, we performed a networking display of the proteins obtained by GO enrichment analysis by using the protein interaction relationships in the three protein interaction databases BioGrid, InWeb.IM and OmniPath, and found that the genes of the selenoamino acid metabolic pathways that interact with NIDPH3, such as RPL23, RPL31, RPL14 could also interact with each other, and the Molecular Complex Detection (MCODE) algorithm indicated that most genes of the selenoamino acid metabolic pathway were aggregated into subnetwork 1 (Figure 5F, MCODE_1). Therefore, we speculated that DIAPH3 may interact with key genes of various selenoamino acid metabolic pathways in pancreatic cancer to significantly impact the functions of genes related to selenoamino acid metabolic pathways, and promote selenoprotein (such as TrxR1 or GPX4) synthesis, which direct reduction of hydroperoxides or resist ferropotosis, respectively. Moreover, we conducted CO-IP assay and validated the interaction of exogenous DIAPH3 with exogenous RPL6, and endogenous DIAPH3 with exogenous/endogenous RPL6 (Figure 5G, H and I) in PDAC cell. However, we failed to validate the potential interaction between DIAPH3 and any protein of RPS8, IARS, RPL4 and RPS2 with Co-IP (data not shown). Thus, DIAPH3 may be involved in selenium metabolism of PDAC cells via interaction with RPL6.

3.6 DIAPH3 promotes malignant phenotype of PDAC cells via promoting selenoprotein TrxR1-mediated antioxidant effects

In order to investigate the accurate molecular mechanism underlying regulation of selenoamino acid metabolism by DIAPH3, we first explored the potential regulation of selenium metabolism and selenoprotein TrxR1 and GPX4 by DIAPH3. Interestingly, we verified knock down or overexpression of DIAPH3 could significantly decrease or increase selenium levels in PDAC cells (Figure 6A and B). In addition, DIAPH3 knock down could significantly decrease TrxR1 expression in Mia Paca-2 and CFPAC-1 cells (Figure 6C and D, Figure S3B) and overexpression of DIAPH3 could increase the expression of TrxR1 in SW1990 cells (Figure 6E). However, GPX4 expression was not impacted by overexpression or knock down of DIAPH3 (Figure S3A). Thus, DIAPH3 may promote TrxR1 expression via increasing selenium levels in PDAC cells. TrxR1 belongs to the pyridine nucleotide-disulphide oxidoreductase family, and is a member of the thiorodoxin (Trx) system. TrxR1 reduce thioredoxins as well as other substrates and play a key role in redox homoeostasis via decreasing the concentrations of reactive oxygen species (ROS). Thus, we explored the impact of DIAPH3 on ROS levels of PDAC cells. As expected, knock down of DIAPH3 significantly increases cellular ROS levels (Figure 6F,G, Figure S3D and E), while DIAPH3 overexpression decrease ROS levels (Figure S3C). Thus, DIAPH3 could regulate ROS level of PDAC cells. Next, we aimed to investigate the implication of TrxR1 in regulation of ROS levels by DIAPH3. We overexpressed TrxR1 in DIAPH3 knock down Mia Paca-2 and CFPAC-1 cells and verified the expression of TrxR1 (Figure S3F). As speculated, overexpression of TrxR1 alleviated increased ROS levels upon treatment with H2O2 in DIAPH3 knock down cells (Figure 6l, Figure S3G). More importantly, TrxR1 overexpression rescued the proliferation inhibition phenotype imposed by DIAPH3 knock down in Mia Paca-2 and CFPAC-1 cells(Figure 6H). Collectively, these data indicate DIAPH3 could promote PDAC cells malignant phenotype via promoting selenoprotein TrxR1-mediated antioxidant effects.

3.7 DIAPH3 knock down could decrease tumour growth and TrxR1 expression in vivo

Finally, in order to verify whether our discoveries were applicable in vivo, we inoculated control and DIAPH3 knock down Mia Paca-2 and CFPAC-1 cells into nude mice and investigated the impact of DIAPH3 on xenograft growth. In accordance with our in vitro data, DIAPH3 knock down significantly alleviated tumour growth of Mia Paca-2 (Figure 7A, B and E) and even prevents tumour of CFPAC-1 cells from growing out (Figure 7C, D and F). In addition, IHC assay demonstrated DIAPH3 knock down significantly decreased TrxR1 expression, while expression of 4-HNE (a marker of lipid peroxidation and ROS in IHC assay) was increased in vivo(Figure 7G). Taken together, our observations indicate DIAPH3 knock down could decrease tumour growth and TrxR1 expression in vivo.

4 DISCUSSION

PDAC is a ductal adenocarcinoma that originates in the epithelium of the glandular duct, and its morbidity accounts for 85% of all
pancreatic cancers and has the poorest prognosis. Although better animal models have been established over the past few decades and humans have made great progress in understanding the biology of PDAC, there is still no effective means of treatment. Among patients with PDAC, about 15% to 20% of patients meet the indications for surgery, which is a small proportion, and more than 80% of patients relapse after undergoing surgical resection. At present, various types of chemotherapeutic drugs for PDAC still have problems such as unsatisfactory safety. Although 5-FU (5-fluorouracil, 5-pyridine), FOLFIRINOX (FOL-folinic acid, F-fluorouracil, IRIN-irinotecan, OX-oxaliplatin, folinic acid-5-fluorouracil-oxaliplatin combined treatment regimen), gemcitabine and gemcitabine-based adjunctive therapies have showed some effect in prolonging the patient’s survival and improving their survival condition, the effect is not satisfactory. In recent years, immunotherapy has demonstrated outstanding effects in other types of malignant tumours, but its effect on PDAC patients is still poor. Therefore, it is a matter of great urgency to explore new treatment options based on previous experience.

**FIGURE 6** DIAPH3 Promotes PDAC Cells Malignant Phenotype via TrxR1-Mediated ROS Levels. (A) Detection of selenium concentration of DIAPH3 knock down PDAC cell line CFPAC-1 using ICP-MS (Inductively coupled plasma mass spectrometry). (B) Selenium concentration of DIAPH3 overexpressing cell line SW1990 measured by ICP-MS (Inductively coupled plasma mass spectrometry). (C and D) Control and DIAPH3 knock down pancreatic cancer cells Mia Paca-2 (C) and CFPAC-1 (D) were treated with or without 20 μM H2O2, after which the expression of TrxR1 and DIAPH3 was detected with Western blot. (E) Control and DIAPH3 overexpressed PDAC cell SW1990 were treated with or without 20 μM H2O2, after which the expression of TrxR1 and DIAPH3 were detected with Western blot. (F) Detection of the ROS level of DIAPH3 knock down cell line CFPAC-1 treated with or without 20 μM H2O2 using flow cytometry after stained with H2DCFDA. (G) Control and DIAPH3 knock down CFPAC-1 cell lines were treated with or without 20 μM H2O2, after which ROS level of these cells was detected with immunofluorescence microscope after stained with H2DCFDA. (H) CCK-8 assay was performed on control and TrxR1 overexpressing PDAC Mia Paca-2 and CFPAC-1 cells after DIAPH3 knock down. (I) ROS levels of control and TrxR1 overexpressing PDAC CFPAC-1 cells after DIAPH3 knock down were detected with H2DCFDA after treatment with or without 20 μM H2O2.
In order to explore the key genes and potential targets in the development of PDAC, we performed a bioinformatics analysis and found that DIAPH3 in the formins family had a significantly high expression level in PDAC tissues than that in the para-carcinoma tissues, and the high expression of DIAPH3 was significantly associated with a poor patient prognosis. In order to verify the above clinical findings, we carried out soft agar assay and confirmed that DIAPH3 could significantly promote the malignant phenotype of pancreatic cancer cells, and conducted a Transwell assay and showed that DIAPH3 can significantly promote the invasive capacity of pancreatic cancer cells, and also conducted MTS assay that showed DIAPH3 can significantly promote the proliferation ability of pancreatic cancer cells. The above results showed that DIAPH3 may be an important gene in the progression of pancreatic cancer. Previous studies reported that DIAPH3 promoted the growth, invasion and metastasis of liver cancer by activating β-catenin/TCF signalling pathway. Interfering with DIAPH3 promoted tumour invasion and metastasis in mouse models. In addition, an overexpression of DIAPH3 inhibited the metastasis and invasive capacity of triple-negative breast cancer by inhibiting the expression of RhoA-GTP. Our results indicated that DIAPH3 promoted the malignant phenotype of pancreatic cancer cells. We analysed the interacting proteins of DIAPH3 in pancreatic cancer cell lines with mass spectrometry and performed a GO analysis. Results showed that the interacting proteins of DIAPH3 were mainly involved in the biological processes such as selenoamino acid metabolism, RNA splicing and...
ribonucleoprotein complex assembly. In contrast, the interacting proteins of DIAPH3 in other tumours, such as prostate cancer and glioblastoma, are tubulin and related microtubule dynamic regulating proteins. DIAPH3 promotes the stability of microtubules by interacting with microtubules. Therefore, we speculate that DIAPH3 may interact with different proteins in different tumours, thereby promoting or inhibiting tumour progression by different molecular mechanism. Therefore, we should adopt different DIAPH3-targeting strategies to treat diseases according to its function and molecular mechanism of DIAPH3 in different tumours.

By using mass spectrometry, we detected the interaction of DIAPH3 with key proteins related to various selenoamino acid metabolism pathways in pancreatic cancer cell lines, such as RPS8, IARS, RPL4, RPL6, and RPS2, which suggested that we can inhibit the progression of pancreatic cancer by regulating the metabolism of selenoamino acids. Based on the bioinformatic analysis, proteins interacted with DIAPH3 identified with Mass spectrometry may be involved in selenoamino acid metabolism and we confirmed RPL6 was the only validated protein interacted with DIAPH3. Previous report indicates a significant functional cluster of ribosomal proteins including RPL6 was involved in selenium and selenoprotein levels maintenance. Specifically, deficiency in these ribosomal proteins alters the ribosome structure facilitating an increased Sec insertion. It is also possible that these knock downs decreased the rate of protein synthesis, which indirectly supported the inherently slow Sec insertion. Thus, the previous data point to potential control of selenoprotein expression through ribosome structure and function. Based on this paper and our observations, we infer that DIAPH3-RPL6 interaction may alter the ribosome structure and increase Sec insertion and consequent selenoprotein TrxR1 expression. It is also possible that DIAPH3-RPL6 interaction decreased the rate of protein synthesis, which indirectly supported the inherently slow Sec insertion and consequent selenoprotein TrxR1 expression. However, the specific mechanism of DIAPH3-RPL6 interaction on TrxR1 expression requires further studies. Moreover, recent observations indicated breast and other cancer cells uptake selenium and promote selenocysteine biosynthesis, which, by allowing production of selenoproteins such as GPX4, protects cells against ferroptosis. Thus, selenium metabolism could promote malignancies of cancer cells uptake selenium and promote selenocysteine biosynthesis, which, by allowing production of selenoproteins such as GPX4, protects cells against ferroptosis. Thus, selenium metabolism could promote malignancies of cancer cells via regulation of selenoproteins. We speculate DIAPH3 may promote selenoprotein (such as TrxR1 or GPX4) synthesis, which direct reduction of hydroperoxides or resist ferroptosis, respectively. Interestingly, we validated in vitro that DIAPH3 could promote PDAC cells malignant phenotype via TrxR1-mediated ROS levels and DIAPH3 knock down could decrease tumour growth and TrxR1 expression in vivo. Thus, our preliminary investigation demonstrates DIAPH3 at least partially promotes PDAC progression via TrxR1-mediated ROS scavenging and TrxR1 may be a promising target for improved target therapy of PDAC, which is worthy of further investigation.

ACKNOWLEDGMENTS

This work was sponsored by the Program of Shanghai Subject Chief Scientist (Grant No. 17XD1401200), the Hunan Science and Technology Department (2018RS3028), Central South University (20170033010007) and the Nature Science Foundation, China, (81602406).

CONFLICT OF INTEREST

The authors declare no conflict of interest.

AUTHORS’ CONTRIBUTION

Yefei Rong: Data curation (equal); Formal analysis (equal). Jie Gao: Investigation (equal). Tian Tao Kuang: Data curation (equal); Formal analysis (equal). Jian-ang Li: Methodology (equal); Resources (equal); Software (equal). Jianlin Chen: Investigation (equal); Resources (equal); Software (equal). Yufeng Huang: Resources (equal); Software (equal); Supervision (equal). Haiguang Xin: Investigation (equal); Methodology (equal); Project administration (equal); Validation (equal). Yuan Fang: Investigation (equal); Resources (equal); Supervision (equal). Xu Han: Investigation (equal); Methodology (equal); Software (equal); Supervision (equal); Visualization (equal). Lunquan Sun: Software (equal); Supervision (equal); Validation (equal); Visualization (equal). Yue-Zhen Deng: Supervision (equal); Writing-original draft (equal); Writing-review & editing (equal). Zhi Li: Conceptualization (equal); Data curation (equal); Formal analysis (equal); Supervision (equal); Validation (equal); Visualization (equal). Wenhui Lou: Conceptualization (equal); Funding acquisition (lead); Supervision (equal); Visualization (equal); Writing-review & editing (equal).

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Yefei Rong https://orcid.org/0000-0002-3096-7883

REFERENCES

1. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matriasi LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913-2921.
2. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol. 1997;15:2403-2413.
3. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362:1605-1617.
4. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691-1703.
5. Moore MJ, Goldstein D, Hamm J, et al. National Cancer Institute of Canada Clinical Trials G. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-1966.
6. Garrido-Laguna I, Hidalgo M. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nat Rev Clin Oncol. 2015;12:319-334.
7. Maitra A, Hruban RH. Pancreatic cancer. Annu Rev Pathol. 2008;3:157-188.
8. Aguirre AJ, Nowak JA, Camarda ND, et al. Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine. *Cancer Discov*. 2018;8:1096-1111.

9. Bogdan S, Schultz J, Grosshans J. Formin’ cellular structures: Physiological roles of Diaphanous (Dia) in actin dynamics. *Commun Integr Biol*. 2013;6:e27634.

10. Tominaga T, Sahai E, Chardin P, McCormick F, Courtneidge SA, Alberts AS. Diaphanous-related formins bridge Rho GTPase and Src tyrosine kinase signaling. *Mol Cell*. 2000;5:13-25.

11. Tominaga T, Sahai E, Chardin P, McCormick F, Courtneidge SA, Alberts AS. Diaphanous-related formins bridge Rho GTPase and Src tyrosine kinase signaling. *Mol Cell*. 2000;5:13-25.

12. Watanabe S, Okawa K, Miki T, et al. Rho and anillin-dependent control of mDia2 localization and function in cytokinesis. *Mol Biol Cell*. 2010;21:3193-3204.

13. Castrillon DH, Gonczy P, Alexander S, et al. Toward a molecular genetic analysis of spermatogenesis in Drosophila melanogaster: characterization of male-sterile mutants generated by single P element mutagenesis. *Genetics*. 1993;135:489-505.

14. Alberts AS. Identification of a carboxyl-terminal diaphanous-related formin homology protein autoregulatory domain. *J Biol Chem*. 2001;276:2824-2830.

15. Castrillon DH, Wasserman SA. Diaphanous is required for cytokinesis in Drosophila and shares domains of similarity with the products of the limb deformity gene. *Development*. 1994;120:3367-3377.

16. Shinoara R, Thumkeo D, Kamijo H, et al. A role for mDia, a Rho-regulated actin nucleator, in tangential migration of interneuron precursors. *Nat Neurosci*. 2012;15(373–80):S1-2.

17. Watanabe S, Okawa K, Miki T, et al. Rho and anillin-dependent control of mDia2 localization and function in cytokinesis. *Mol Biol Cell*. 2010;21:3193-3204.

18. Schoen CJ, Emery SB, Thorne MC, et al. Increased activity of Diaphanous homolog 3 (DIAPH3)/diaphanous causes hearing defects in humans with auditory neuropathy and in Drosophila. *Proc Natl Acad Sci U S A*. 2010;107:13396-13401.

19. Bartolini F, Moseley JB, Schmaranzer J, Cassimeris L, Goode BL, Gundersen GG. The formin mDia2 stabilizes microtubules independently of its actin nucleation activity. *J Cell Biol*. 2008;181:523-536.

20. Bartolini F, Ramalingam N, Gundersen GG. Actin-capping protein promotes microtubule stability by antagonizing the actin activity of mDia1. *Mol Biol Cell*. 2012;23:4032-4040.

21. Wen Y, Eng CH, Schmaranzer J, et al. EB1 and APC bind to mDia to stabilize microtubules downstream of Rho and promote cell migration. *Nat Cell Biol*. 2004;6:820-830.

22. Reis-Sobroiero M, Chen JF, Novitskaya T, et al. Emerin deregulation links nuclear shape instability to metastatic potential. *Cancer Res*. 2018;78:6086-6097.

23. Dong L, Li Z, Xue L, et al. DIAPH3 promoted the growth, migration and metastasis of hepatocellular carcinoma cells by activating beta-catenin/TCF signaling. *Mol Cell Biochem*. 2018;438:183-190.

24. Hager MH, Morley S, Bielenberg DR, et al. DIAPH3 governs the cellular transition to the amoeboid tumour phenotype. *EMBO Mol Med*. 2012;4:743-760.

25. Stasna J, Pan X, Wang H, et al. Differing and isomorf-specific roles for the formin DIAPH3 in plasma membrane blebbing and filopodia formation. *Cell Res*. 2012;22:728-745.

26. Jiang J. Diaphanous-related formin-3 overexpression inhibits the migration and invasion of triple-negative breast cancer by inhibiting RhoA-GTP expression. *Biomed Pharmacother*. 2017;94:439-445.

27. Kong H, Chandel NS. Regulation of redox balance in cancer and T cells. *J Biol Chem*. 2018;293:7499-7507.

28. Busker S, Qian W, Haraldsson M, et al. Irreversible TrxR1 inhibitors block STAT3 activity and induce cancer cell death. *Sci Adv*. 2020;6:eaaax7945.

29. Liou GY, Storz P. Detecting reactive oxygen species by immunohistochemistry. *Methods Mol Biol*. 2015;1292:97-104.

30. Adamska A, Domenichini A, Falasca M, Falasca M. Pancreatic ductal adenocarcinoma: Current and evolving therapies. *Int J Mol Sci*. 2017;18(7):1338.

31. Malinouski M, Hasan NM, Zhang Y, et al. Genome-wide RNAiomics screen reveals new genes and regulation of human trace element metabolism. *Nat Commun*. 2014;5:3301.

32. Carlisle AE, Lee N, Matthew-Onabanjo AN, et al. Selenium detoxification is required for cancer-cell survival. *Nat Metab*. 2020;2:603-611.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section.